Crystalline anhydrous form A1
EU DMF readiness
US DMF readiness
Polpharma API characteristics:
- Crystalline anhydrous modification A1, same as originator
- Impurity profile control strategy based on optimum number of steps and materials selection
Safinamide is an alpha-aminoamide derivative acts as add-on therapy to dopamine agonists or levodopa.
Safinamide is indicated in the treatment of idiopathic Parkinson’s disease (PD) or for mid-to late-stage fluctuating patients as add-on therapy to a stable dose of Levodopa (L-dopa) alone or in combination with other PD medicinal products.
It is formulated as film-coated tablets for oral route of administration.
Mechanism of action:
Safinamide has a dual mechanism of action based on the enhancement of the dopaminergic function (through potent reversible inhibition of MAO-B and of dopamine uptake) and inhibition of excessive release of glutamate.
The above product is presented solely for informational purposes and does not constitute an offer in any sense. Products with PIPELINE & EARLY DEVELOPMENT STATUS under patent (SPC) protection in Poland and/or other countries are not offered until expiration of the corresponding IP right.